Report cover image

Active Pharmaceutical Ingredient (API) Market

Publisher Fortune Business Insights Pvt. Ltd.
Published Sep 01, 2024
Length 138 Pages
SKU # FOB19185573

Description

Active Pharmaceutical Ingredient (API) Market



Growth Factors of Active Pharmaceutical Ingredient (API) Market

The active pharmaceutical ingredient [API] market size was valued at USD 196.99 billion in 2023, and the market is now projected to grow from USD 209.80 billion in 2024 to USD 359.12 billion by 2032, exhibiting a CAGR of 6.9% during the forecast period of 2024-2032.

The active pharmaceutical ingredient market had observed an adverse impact of COVID pandemic due to the end of a number of workshops. The scarcity of raw materials had also directed to the termination of factories in China. Also, the decline in demand for pharmaceuticals for certain optional procedures have also led to deterioration in the progression of the market.

The burden of chronic diseases worldwide is growing quickly due to the upsurge in elderly population, rising implementation of inactive lifestyle, coupled with urbanization. This is creating an ever increasing demand for therapeutic drugs in the active pharmaceutical ingredient market. The change in the difficulty of prolonged diseases and upsurge in frequency of new cases of these diseases, has led to the surge in demand for inventive drugs comprising biological drugs. Moreover, rising prominence on research and development activities by many pharmaceutical firms for the introduction of advanced drugs in the market is likely to motivate the active pharmaceutical ingredients [API] market growth during the prediction period.

As the pharmaceutical industry is observing progress every day, numerous countries have executed rigid governing guidelines for the making of pharmaceutical ingredients. These rules have been imposed upon the companies to control their manufacturing quality, thus augmenting the probable clinical efficiency of the final product. This is further improved by the growing overhead costs of in-house API manufacturing, which has directed the pharmaceutical companies to decrease their emphasis on internal manufacturing.

Comprehensive Analysis of Active Pharmaceutical Ingredient (API) Market

The market can be segmented in various ways, depending on the focus of analysis such as by type, by synthetic. Based on type, the market is segmented into generic API and branded API. In terms of type of synthesis, the market is segmented into synthetic and biological.

North America region is dominating the active pharmaceutical ingredient [API] market share due to rising prevalence of prolonged diseases and growing government initiatives for the growth of innovative drugs. Along with it, the prompt implementation of biological drugs among patients for the cure of several prolonged disorders is motivating the demand for the biological API segment.

The key players are enthusiastically contributing in planned events that are targeted at maintaining durable market position and growing market share by merger, partnerships and others. These players include Teva Pharmaceutical Industries Ltd, (Petah Tikva, Israel), AbbVie Inc. (North Chicago, U.S.), Abbott (Abbott Park, U.S.), Aurobindo Pharma (Hyderabad, India), Cipla Inc. (Mumbai, India), Dr. Reddy’s Laboratories Ltd (Hyderabad, India), Sun Pharmaceutical Industries Ltd (Mumbai, India), Amgen Inc. (Thousand Oaks, U.S.), Biocon (Bengaluru, India), Mylan N.V. (Canonsburg, U.S.), Boehringer Ingelheim International GmbH (Ingelheim am Rhein, Germany) these market players spending harshly on research and development in order to rise with more innovative technology so that they can maintain and progress their existing market.

In October 2023, Lonza announced the launch of a new filling line for commercial supply of antibody-drug conjugates for its customers.

Segmentation Table

ATTRIBUTE DETAILS

Study Period 2019-2032

Base Year 2023

Estimated Year 2024

Forecast Period 2024-2032

Historical Period 2019-2022

Growth Rate CAGR of 6.9% from 2024 to 2032

Unit Value (USD billion)

Segmentation

By Type

- Generic API

- Branded API

By Synthesis

- Biological API

- Synthetic API

By Geography

- North America (By Type, By Synthesis, and By Country)
  • U.S.
  • Canada
- Europe (By Type, By Synthesis, and By Country/Sub-Region)
  • U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Scandinavia
  • Rest of Europe
- Asia Pacific (By Type, By Synthesis, and By Country/Sub-Region)
  • Japan
  • China
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
- Rest of World (By Type, and By Synthesis)


Please Note: It will take 5-6 business days to complete the report upon order confirmation.

Table of Contents

138 Pages
1. Introduction
1.1. Research Scope
1.2. Market Segmentation
1.3. Research Methodology
1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Market Trends
4. Key Insights
4.1. Prevalence of Key Chronic Diseases, By Key Countries/Regions, 2023
4.2. Key Industry Developments - Partnerships, Mergers, And Acquisitions
4.3. Therapeutic Applications of the Different Types of Active Pharmaceutical Ingredient
4.4. Impact of COVID-19 on the Market
5. Global Active Pharmaceutical Ingredient Market Analysis, Insights and Forecast, 2019-2032
5.1. Market Analysis, Insights and Forecast – By Type
5.1.1. Generic API
5.1.2. Branded API
5.2. Market Analysis, Insights and Forecast – By Synthesis
5.2.1. Biological API
5.2.2. Synthetic API
5.3. Market Analysis, Insights and Forecast – By Region
5.3.1. North America
5.3.2. Europe
5.3.3. Asia Pacific
5.3.4. Rest of World
6. North America Active Pharmaceutical Ingredient Market Analysis, Insights and Forecast, 2019-2032
6.1. Market Analysis, Insights and Forecast – By Type
6.1.1. Generic API
6.1.2. Branded API
6.2. Market Analysis, Insights and Forecast – By Synthesis
6.2.1. Biological API
6.2.2. Synthetic API
6.3. Market Analysis, Insights and Forecast – By Country
6.3.1. U.S.
6.3.2. Canada
7. Europe Active Pharmaceutical Ingredient Market Analysis, Insights and Forecast, 2019-2032
7.1. Market Analysis, Insights and Forecast – By Type
7.1.1. Generic API
7.1.2. Branded API
7.2. Market Analysis, Insights and Forecast – By Synthesis
7.2.1. Biological API
7.2.2. Synthetic API
7.3. Market Analysis, Insights and Forecast – By Country/Sub-Region
7.3.1. U.K.
7.3.2. Germany
7.3.3. France
7.3.4. Italy
7.3.5. Spain
7.3.6. Scandinavia
7.3.7. Rest of Europe
8. Asia Pacific Active Pharmaceutical Ingredient Market Analysis, Insights and Forecast, 2019-2032
8.1. Market Analysis, Insights and Forecast – By Type
8.1.1. Generic API
8.1.2. Branded API
8.2. Market Analysis, Insights and Forecast – By Synthesis
8.2.1. Biological API
8.2.2. Synthetic API
8.3. Market Analysis, Insights and Forecast – By Country/Sub-Region
8.3.1. Japan
8.3.2. China
8.3.3. India
8.3.4. Australia
8.3.5. Southeast Asia
8.3.6. Rest of Asia Pacific
9. Rest of World Active Pharmaceutical Ingredient Market Analysis, Insights and Forecast, 2019-2032
9.1. Market Analysis, Insights and Forecast – By Type
9.1.1. Generic API
9.1.2. Branded API
9.2. Market Analysis, Insights and Forecast – By Synthesis
9.2.1. Biological API
9.2.2. Synthetic API
10. Competitive Analysis
10.1. Global Market Share Analysis (2023)
10.2. Company Profiles
10.2.1. Teva Pharmaceutical Industries Ltd
10.2.1.1. Overview
10.2.1.2. Products & Services
10.2.1.3. SWOT Analysis
10.2.1.4. Recent Developments
10.2.1.5. Strategies
10.2.1.6. Financials (Based on Availability)
10.2.2. AbbVie Inc.
10.2.2.1. Overview
10.2.2.2. Products & Services
10.2.2.3. SWOT Analysis
10.2.2.4. Recent Developments
10.2.2.5. Strategies
10.2.2.6. Financials (Based on Availability)
10.2.3. Abbott
10.2.3.1. Overview
10.2.3.2. Products & Services
10.2.3.3. SWOT Analysis
10.2.3.4. Recent Developments
10.2.3.5. Strategies
10.2.3.6. Financials (Based on Availability)
10.2.4. Aurobindo Pharma
10.2.4.1. Overview
10.2.4.2. Products & Services
10.2.4.3. SWOT Analysis
10.2.4.4. Recent Developments
10.2.4.5. Strategies
10.2.4.6. Financials (Based on Availability)
10.2.5. Cipla Inc.
10.2.5.1. Overview
10.2.5.2. Products & Services
10.2.5.3. SWOT Analysis
10.2.5.4. Recent Developments
10.2.5.5. Strategies
10.2.5.6. Financials (Based on Availability)
10.2.6. Dr. Reddy’s Laboratories Ltd
10.2.6.1. Overview
10.2.6.2. Products & Services
10.2.6.3. SWOT Analysis
10.2.6.4. Recent Developments
10.2.6.5. Strategies
10.2.6.6. Financials (Based on Availability)
10.2.7. Sun Pharmaceutical Industries Ltd
10.2.7.1. Overview
10.2.7.2. Products & Services
10.2.7.3. SWOT Analysis
10.2.7.4. Recent Developments
10.2.7.5. Strategies
10.2.7.6. Financials (Based on Availability)
10.2.8. Amgen Inc.
10.2.8.1. Overview
10.2.8.2. Products & Services
10.2.8.3. SWOT Analysis
10.2.8.4. Recent Developments
10.2.8.5. Strategies
10.2.8.6. Financials (Based on Availability)
10.2.9. Biocon
10.2.9.1. Overview
10.2.9.2. Products & Services
10.2.9.3. SWOT Analysis
10.2.9.4. Recent Developments
10.2.9.5. Strategies
10.2.9.6. Financials (Based on Availability)
10.2.10. Mylan N.V.
10.2.10.1. Overview
10.2.10.2. Products & Services
10.2.10.3. SWOT Analysis
10.2.10.4. Recent Developments
10.2.10.5. Strategies
10.2.10.6. Financials (Based on Availability)

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us